Filipendulae ulmariae herba (Meadowsweet)

Filipendulae ulmariae herba
Meadowsweet
Filipendula ulmaria (L.) Maxim. (Syn: Spiraea ulmaria L.)
Published 2015
Format: PDF

SUMMARY:
The herbal monograph selects and summarises scientific studies and textbooks regarding efficacy, dosage and safety supporting the therapeutic uses of meadowsweet.
This herbal drug by definition consists of the whole or cut, dried flowering tops of Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria L.).
Studies with its main characteristic constituents flavonoids, particularly spiraeoside and quercetin derivatives are included.
The therapeutic indications are supportive therapy for the common cold and enhancement of renal elimination of water.
Administration of meadowsweet addresses posology; its duration of use; contra-indications; special warnings; special precautions for use; interactions with other medicinal products; other forms of interaction; in pregnancy and lactation; its effects on ability to drive;  undesirable effects; overdose.
In vitro experiments with meadowsweet demonstrate antimicrobial, anti-inflammatory and immunomodulatory properties.
In vivo experiments with animals demonstrate gastroprotective and anticarcinogenic effects.
A clinical study demonstrated its local use for the treatment of precancerous changes in patients with cervical dysplasia.
Pharmacokinetics indicated conversion by decarboxylation in the gut flora.
Preclinical safety data for meadowsweet extract were assessed in animal toxicity studies.
The selection of literature cited in the monograph is aimed at bringing together relevant information about the possible physiological roles of meadow sweet and its major constituents.

KEYWORDS:

• Filipendula ulmaria (L.) Maxim. (Syn: Spiraea ulmaria L.)
• Filipendulae ulmariae herba
• Meadowsweet
• Common cold, supportive therapy